Triple-negative breast cancer (TNBC) accounts for 10–15% of all breast cancers and is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [1]. This evidence concerns the gene PGR and triple-negative breast carcinoma.